Validation of the Ulcerative Colitis Colonoscopic Index of Severity and Its Correlation With Disease Activity Measures

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 1, 2013, Pages

  Samuel, Sunil ^a,b   Bruining, David H ^a   Loftus, Edward V ^a   Thia, Kelvin T ^c   Schroeder, Kenneth W ^a   Tremaine, William J ^a   Faubion, William A ^a   Kane, Sunanda V ^a   Pardi, Darrell S ^a   de Groen, Piet C ^a   Harmsen, William S ^a   Zinsmeister, Alan R ^a   Sandborn, William J ^d  

^a MAYO CLINIC   (United States)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; HEMOGLOBIN;

ADULT; AGED; ARTICLE; ASCENDING COLON; CECUM; CLINICAL ARTICLE; CLINICAL TRIAL; COLONOSCOPY; DESCENDING COLON; DIGESTIVE TRACT ENDOSCOPY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; RECTUM; REMISSION; SCORING SYSTEM; SIGMOID; THROMBOCYTE COUNT; TRANSVERSE COLON; ULCERATIVE COLITIS; ULCERATIVE COLITIS COLONOSCOPIC INDEX; VIDEOENDOSCOPY; VISUAL ANALOG SCALE;

EID: 84870888253     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.08.003     Document Type: Article

References (25)

1. Regueiro M., Rodemann J., Kip K.E., et al. Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity. Inflamm Bowel Dis 2011, 17:1008-1014.
2. Fefferman D.S., Farrell R.J. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol 2005, 3:11-24.
3. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
4. Riley S.A., Mani V., Goodman M.J., et al. Microscopic activity in ulcerative colitis: what does it mean?. Gut 1991, 32:174-178.
5. Frøslie K.F., Jahnsen J., Moum B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
6. Colombel J.F., Rutgeerts P., Reinisch W., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011, 141:1194-1201.
7. Rutgeerts P., Vermeire S., Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?. Gut 2007, 56:453-455.
8. Rubin D.T. We once were blind and now we see: is it time to treat ulcerative colitis to achieve mucosal healing?. Clin Gastroenterol Hepatol 2011, 9:456-457.
9. Baron J.H., Connell A.M., Lennard-Jones J.E. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964, 1:89-92.
10. D'Haens G., Sandborn W.J., Feagan B.G., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763-786.
11. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987, 317:1625-1629.
12. Orlandi F., Brunelli E., Feliciangeli G., et al. Observer agreement in endoscopic assessment of ulcerative colitis. Ital J Gastroenterol Hepatol 1998, 30:539-541.
13. de Lange T., Larsen S., Aabakken L. Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis. BMC Gastroenterol 2004, 4:9.
14. Thia K.T., Loftus E.V., Pardi D.S., et al. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis 2011, 17:1257-1264.
15. Feagan B.G., Greenberg G.R., Wild G., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499-2507.
16. Stanek S.R., Tavanapong W., Wong J., et al. Automatic real-time detection of endoscopic procedures using temporal features. Comput Methods Programs Biomed 2012, 108:524-535.
17. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989, 298:82-86.
18. Walmsley R.S., Ayres R.C., Pounder R.E., et al. A simple clinical colitis activity index. Gut 1998, 43:29-32.
19. Higgins P.D., Schwartz M., Mapili J., et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005, 54:782-788.
20. Walsh A.J., Brain O., Keshav S., et al. How variable is the Mayo score between observers and might this affect trial recruitment or outcome?. Gastroenterology 2009, 136:A677.
21. Travis S.P., Schnell D., Krzeski P., et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012, 61:535-542.
22. Sandborn W.J., Regula J., Feagan B.G., et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009, 137:1934-1943.
23. Bernstein C.N., Shanahan F., Anton P.A., et al. Patchiness of mucosal inflammation in treated ulcerative colitis: a prospective study. Gastrointest Endosc 1995, 42:232-237.
24. Kim B., Barnett J.L., Kleer C.G., et al. Endoscopic and histological patchiness in treated ulcerative colitis. Am J Gastroenterol 1999, 94:3258-3262.
25. Loftus E.V., Harewood G.C., Loftus C.G., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005, 54:91-96.